Abstract: As a key distribution enterprise in Zhejiang Province and one of the top 100 service enterprises in the province, the company has a high reputation in Zhejiang Province. Currently, the company's main business is concentrated in the traditional trade service industry. The main sources of revenue are Hangzhou Department Store, Hangzhou Grand Hotel and Hangzhou Collectibles Market. The company entrusted the Hangzhou Department Store to Zhejiang Yintai Department Store for operation and management. During the 20-year period agreed in the “Entrusted Management Agreement”, the profit base for commissioned operations was 89.65 million yuan. Currently, the annual profit slightly exceeds this base and collects a fixed guaranteed profit every year, bringing long-term and stable profits to the company, as well as good cash flow. In the first half of 2015, we achieved operating revenue of 530 million yuan and realized total profit of 85.09 million yuan. Among them, retail sales of products were 493 million yuan, an increase of 1.52% over the previous year. While maintaining the profit growth of the traditional department store business, the company laid out the medical sector. Zhejiang Xizi International Medical Center is an oncology specialist hospital founded by Zhejiang Cancer Hospital in cooperation with the Top 100 Group. The Zhejiang Cancer Hospital implements integrated management and interconnection of medical data and medical information systems. By introducing world-leading medical equipment and technology, establishing close cooperative relationships with advanced international cancer hospitals, expanding the scope of cooperation between domestic and provincial higher medical colleges, etc., we are actively developing the clinical level and discipline construction of cancer screening, diagnosis, treatment, and rehabilitation, and promoting precise treatment of cancer diseases. Profit forecast: Based on the department store industry in Zhejiang Province, the top 100 groups will accelerate the layout of the medical industry and achieve dual main business operations. The oncology specialist hospital established by the company has a good reputation, excellent technology, and large market space for cancer treatment. According to the model, we expect EPS of 0.44 yuan, 0.45 yuan, and 0.47 yuan respectively in 2015-2017, maintaining an “increase” rating. Risk warning: The construction progress of Zhejiang Xizi International Medical Center fell short of expectations; with the rise of private hospitals, competition among similar companies intensified.